Overexpression of mn1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and bim induction

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Pardee, Timothy S ^a,b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CYTARABINE; DOXORUBICIN; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG TRANSPORT; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MENIGIOMA 1 GENE; MOUSE; NONHUMAN; PROTEIN INDUCTION; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CYTARABINE; DISEASE MODELS, ANIMAL; DOXORUBICIN; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; LEUKEMIA, MYELOID, ACUTE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84865057017     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043185     Document Type: Article

References (44)

1. Siegel R, Ward E, Brawley O, Jemal A, ((2011)) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:: 212--236.
2. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, et al. ((2010)) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:: 453--474.
3. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, et al. ((2002)) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:: 4325--4336.
4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, et al. ((1998)) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:: 2322--2333.
5. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, et al. ((2000)) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:: 4075--4083.
6. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, et al. ((2006)) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108:: 3280--3288.
7. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, et al. ((2008)) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:: 1909--1918.
8. Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, et al. (2011) Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosomes Cancer.
9. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, et al. ((2006)) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:: 3898--3905.
10. Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, et al. ((2009)) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 27:: 3198--3204.
11. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrozek K, et al. ((2011)) Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 118:: 4188--4198.
12. van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, et al. ((2003)) The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 22:: 699--709.
13. Meester-Smoor MA, Molijn AC, Zhao Y, Groen NA, Groffen CA, et al. ((2007)) The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence. J Mol Endocrinol 38:: 113--125.
14. Buijs A, Sherr S, van Baal S, van Bezouw S, van der Plas D, et al. ((1995)) Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene 10:: 1511--1519.
15. Sutton AL, Zhang X, Ellison TI, Macdonald PN, ((2005)) The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation. Mol Endocrinol 19:: 2234--2244.
16. Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, et al. ((2007)) MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110:: 1639--1647.
17. Carella C, Bonten J, Sirma S, Kranenburg TA, Terranova S, et al. ((2007)) MN1 overexpression is an important step in the development of inv(16) AML. Leukemia 21:: 1679--1690.
18. Liu T, Jankovic D, Brault L, Ehret S, Baty F, et al. ((2010)) Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 24:: 601--612.
19. Wang C, Curtis JE, Minden MD, McCulloch EA, ((1989)) Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3:: 264--269.
20. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, et al. ((1997)) Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 11:: 1469--1477.
21. Pardee TS, Zuber J, Lowe SW (2011) The Flt3 Internal Tandem Duplication Alters Chemotherapy Response In Vitro and In Vivo in a p53-Dependent Manner. Exp Hematol.
22. Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, et al. ((2009)) Mouse models of human AML accurately predict chemotherapy response. Genes Dev 23:: 877--889.
23. Lee BD, Sevcikova S, Kogan SC, ((2007)) Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leuk Res 31:: 1131--1134.
24. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH, ((2012)) Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP [10] results in high efficacy against AML and low toxicity. Blood 119:: 3561--3570.
25. Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, et al. ((2006)) DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 20:: 2130--2136.
26. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, et al. ((2009)) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113:: 6206--6214.
27. Yin B, Kogan SC, Dickins RA, Lowe SW, Largaespada DA, ((2006)) Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol 34:: 631--641.
28. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, et al. ((1998)) Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin Cancer Res 4:: 1315--1322.
29. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, et al. ((2002)) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109:: 335--346.
30. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. ((2004)) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:: 844--848.
31. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, et al. ((2009)) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 114:: 4507--4516.
32. Gocek E, Wang X, Liu X, Liu CG, Studzinski GP, ((2011)) MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res 71:: 6230--6239.
33. Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, et al. ((2006)) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108:: 63--73.
34. Walker A, Marcucci G, ((2011)) Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse. Haematologica 96:: 640--643.
35. Kawagoe H, Grosveld GC, ((2005)) Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. Blood 106:: 4269--4277.
36. Abrahamson JL, Lee JM, Bernstein A, ((1995)) Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol 15:: 6953--6960.
37. Lin Y, Benchimol S, ((1997)) p53-mediated cell cycle arrest and apoptosis. Leukemia 11 (Suppl 3): 324--326.
38. Harper JW, Elledge SJ, ((2007)) The DNA damage response: ten years after. Mol Cell 28:: 739--745.
39. Boehrer S, Ades L, Tajeddine N, Hofmann WK, Kriener S, et al. ((2009)) Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 28:: 2205--2218.
40. Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, et al. ((2010)) Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS One 5:: e12405.
41. Myatt SS, Lam EW, ((2007)) The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7:: 847--859.
42. Santamaria CM, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, et al. ((2009)) High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. Leuk Res 33:: 1706--1709.
43. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, et al. ((2010)) Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 16:: 1865--1874.
44. Thepot S, Lainey E, Cluzeau T, Sebert M, Leroy C, et al. ((2011)) Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 10:: 2323--2330.